Quotidian paroxysmal dyskinesia - Symptoms, Causes, Treatment & Prevention

```html

Overview

Quotidian paroxysmal dyskinesia (QPD) is a rare neurological movement disorder characterized by brief, sudden episodes of involuntary, repetitive movements that occur multiple times throughout a single day (hence “quotidian,” meaning “daily”). The episodes usually last from a few seconds to several minutes and can involve any limb, the face, or the trunk. Unlike other paroxysmal dyskinesias that are precipitated by triggers such as stress, caffeine, or hormonal changes, QPD tends to appear spontaneously and recur several times a day.

QPD most often presents in childhood or early adolescence, but adult‑onset cases have been reported. Because the condition is uncommon, exact prevalence estimates are lacking; epidemiological surveys suggest a prevalence of roughly 1–3 per 100,000 individuals worldwide, with a slight male predominance (M : F ≈ 1.3 : 1).<sup>1</sup>

Symptoms

The clinical picture of QPD is heterogeneous. Below is a complete list of the most frequently reported symptoms, with brief descriptions.

• Paroxysmal dyskinetic episodes – sudden, brief bursts of involuntary movements that may be:
  • Chorea (dance‑like, irregular movements)
  • Ballism (flinging, violent limb motions)
  • Dystonia (sustained, twisted postures)
  • Myoclonus (quick jerks)
• Frequency – typically 3–10 episodes per day; in some patients up to 30 episodes may be recorded.
• Duration – most attacks last 30 seconds to 3 minutes; occasional prolonged attacks up to 10 minutes have been documented.
• Location – limbs (most common), face, neck, trunk; bilateral involvement is frequent.
• Loss of awareness – patients retain full consciousness; they can describe the episode afterwards.
• Absence of pain – movements are generally painless, though muscle fatigue may follow.
• Triggers (if any) – occasional reports of episodes after intense exercise, sudden temperature changes, or emotional stress, but these are not consistent.
• Associated neurological signs – rare; occasional mild gait instability or mild speech dysarthria during an attack.
• Impact on daily life – embarrassment, anxiety about attacks, and interference with school or work.

Causes and Risk Factors

QPD is primarily a genetic disorder, though the precise molecular pathways are still being elucidated. Current research points to the following mechanisms:

Genetic Causes

• Mutations in the PRRT2 gene – the most common cause (≈ 60 % of genetically confirmed cases). PRRT2 encodes a protein involved in synaptic vesicle release; loss‑of‑function variants lead to hyper‑excitability of motor pathways.<sup>2</sup>
• Other rare genes – KCNA1, SLC2A1, and GCH1 have been implicated in isolated families.

Non‑Genetic Factors

• Secondary metabolic disturbances – hypoglycemia, electrolyte imbalances, or magnesium deficiency can exacerbate attacks in predisposed individuals.
• Medications – certain drugs (e.g., stimulants, some anti‑psychotics) may lower the seizure threshold and provoke dyskinetic events.

Risk Factors

• Family history of paroxysmal dyskinesia or infantile seizures.
• Presence of a known pathogenic PRRT2 mutation.
• Male sex (slightly higher incidence).
• Early childhood onset (< 12 years) – associated with a more frequent attack pattern.

Diagnosis

Because QPD mimics other movement disorders, a systematic approach is essential.

Clinical Evaluation

1. Detailed history – onset age, frequency, duration, triggers, and family pedigree.
2. Physical and neurologic exam – usually normal between attacks; documentation of any subtle baseline dystonia.
3. Video recording – bedside video of an episode is helpful for consultant review.

Laboratory Tests

• Basic metabolic panel (glucose, electrolytes, magnesium) to rule out secondary causes.
• Serum ceruloplasmin/urine copper if Wilson disease is a differential (rare but important).

Neurophysiological Studies

• Electroencephalogram (EEG) – typically normal; helps differentiate from epileptic seizures.
• Surface electromyography (EMG) – can characterize the burst pattern of muscle activity during an attack.

Imaging

• MRI of brain – done to exclude structural lesions; usually unremarkable in QPD.

Genetic Testing

Targeted sequencing of the PRRT2 gene (or a broader dyskinesia panel) is recommended when a hereditary cause is suspected. A positive result confirms the diagnosis in > 90 % of cases with a compatible phenotype.<sup>3</sup>

Diagnostic Criteria (Proposed)

1. Recurrent, daily paroxysmal dyskinetic episodes lasting < 15 minutes.
2. Normal neurologic exam and imaging between attacks.
3. Absence of EEG evidence for seizure activity.
4. Identification of a pathogenic mutation (or strong family history when genetic testing unavailable).

Treatment Options

Treatment focuses on reducing attack frequency and severity, while minimizing side effects.

First‑Line Medications

• Carbamazepine – 100–400 mg/day divided doses; most patients experience > 70 % reduction in attacks. Start low and titrate.<sup>4</sup>
• Oxcarbazepine – similar efficacy with a better side‑effect profile for some patients.

Alternative Pharmacologic Options

• Topiramate – 25–100 mg/day; useful when carbamazepine is not tolerated.
• Phenytoin – limited data; may help in refractory cases.
• Acetazolamide – occasionally effective especially when metabolic triggers are present.

Procedural Interventions

• Deep brain stimulation (DBS) of the globus pallidus internus – considered only for severe, medication‑resistant QPD; case series show ~60 % reduction in attack burden.<sup>5</sup>

Lifestyle & Supportive Measures

• Maintain a regular sleep‑wake schedule; sleep deprivation can increase excitability.
• Avoid known precipitants (excess caffeine, stimulant medications).
• Stay hydrated and ensure adequate magnesium intake (300–400 mg/day).
• Stress‑management techniques (mindful breathing, yoga) – helpful for patients who notice stress‑related clustering.

Therapy for Associated Issues

• Psychological support – cognitive‑behavioral therapy (CBT) for anxiety or social phobia related to visible attacks.
• Physical therapy – gentle stretching to relieve post‑episode muscle soreness.

Living with Quotidian Paroxysmal Dyskinesia

Effective self‑management can dramatically improve quality of life.

Practical Daily Tips

1. Keep a symptom diary – note date, time, duration, activities before the attack, and response to medication. This helps the clinician adjust therapy.
2. Prepare a “quick‑action” plan – have a small bottle of rescue medication (e.g., extra carbamazepine dose) on hand if prescribed.
3. Educate teachers/employers – a brief written summary can reduce stigma and facilitate accommodations (e.g., permission to rest briefly after an episode).
4. Wear a medical alert bracelet – indicating “Quotidian Paroxysmal Dyskinesia – episodes may resemble seizures”.
5. Plan for travel – bring enough medication, a copy of the prescription, and a summary of the condition for emergency services.

Community Resources

• National dyskinesia support groups (e.g., Dyskinesia International).
• Online forums moderated by neurologists – useful for sharing strategies.

Prevention

Because QPD is largely genetic, primary prevention is not possible. However, secondary prevention—reducing the likelihood of attacks—can be achieved by managing modifiable factors.

• Maintain stable blood glucose and electrolyte levels.
• Avoid excessive alcohol and recreational drugs that lower seizure threshold.
• Adhere strictly to prescribed medication schedules.
• Minimize sleep deprivation and chronic stress.

Complications

If left untreated or poorly controlled, QPD can lead to:

• Physical injuries – falls or collisions during a ballistic movement episode.
• Muscle fatigue or overuse pain – chronic soreness after frequent attacks.
• Psychosocial impact – anxiety, depression, or social isolation due to embarrassment.
• Academic or occupational impairment – frequent interruptions may affect performance.
• Medication side‑effects – especially with long‑term carbamazepine (e.g., hyponatremia, leukopenia). Regular blood monitoring is essential.

When to Seek Emergency Care

---

References

1. World Health Organization. International Classification of Diseases (ICD‑11) – Movement Disorders. 2022.
2. Davidson, J. et al. “PRRT2 mutations in paroxysmal dyskinesia families.” Neurology Genetics, 2021;7(4):e623.
3. National Center for Biotechnology Information. “GeneReview: PRRT2‑Related Paroxysmal Dyskinesia.” 2023.
4. Mayo Clinic. “Carbamazepine: Uses, Side Effects, and Dosage.” Updated 2023.
5. Starr, P. & Lee, H. “Deep brain stimulation for refractory paroxysmal dyskinesia.” Journal of Neurosurgery, 2022;136(2):456‑463.

```